Jay Vora, Ph.D., MBA

Dr. Vora is senior vice president of portfolio and program management at Tenaya Therapeutics, where he is responsible for program and alliance management. Prior to joining Tenaya, Dr. Vora served in a variety of roles at companies focused on product development for orphan diseases with multiple modalities, including gene therapy, biologics and small molecules. Most recently, Dr. Vora served as head of alliance management and as program leader on one of Sangamo’s gene therapy programs. He was previously vice president of program and alliance management at REGENXBIO, where he supported multiple AAV gene therapy programs. Dr. Vora has also held roles in product development and program management at BioMarin and Chiron and has worked in management consulting at PRTM.

Dr. Vora earned his Ph.D. in pharmacokinetics and clinical pharmacology from Northeastern University, an M.S. in medicinal chemistry from the University of Cincinnati and an MBA from the Haas School of Business at the University of California, Berkeley.